Filing Details

Accession Number:
0000899243-23-001526
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-10 19:22:45
Reporting Period:
2023-01-06
Accepted Time:
2023-01-10 19:22:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1658551 Amylyx Pharmaceuticals Inc. AMLX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1358266 D Patrick Yeramian C/O Amylyx Pharmaceuticals, Inc.
43 Thorndike Street
Cambridge MA 02142
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-06 1,405 $36.08 204,928 No 4 S Direct
Common Stock Acquisiton 2023-01-06 629 $36.79 204,299 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.